FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503) 10903 New Hampshire Avenue, Silver Spring, Maryland April 12, 2016

FINAL MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

LCDR Jennifer A. Shepherd, RPh

Division of Advisory Committee and Consultant Management Office of Executive Programs, CDER, FDA Silver Spring, Maryland

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Deborah K. Armstrong, MD

(Chairperson)

Professor of Oncology

The Sidney Kimmel Comprehensive Cancer Center

at Johns Hopkins

The Johns Hopkins University School of Medicine

Baltimore, Maryland

Tito Fojo, MD, PhD

Professor of Medicine

Division of Medical Oncology

Department of Medicine

Columbia University

New York, New York

Grzegorz S. Nowakowski, MD

Assistant Professor of Medicine

Mayo Clinic Rochester

Rochester, Minnesota

Bruce J. Roth, MD

Professor of Medicine

Division of Oncology

Washington University School of Medicine

St. Louis, Missouri

Bernard F. Cole, PhD

Professor

Department of Mathematics and Statistics

University of Vermont

Burlington, Vermont

Michael E. Menefee, MD

Assistant Professor of Medicine Mayo Clinic Jacksonville Jacksonville, Florida

Brian I. Rini, MD, FACP

Professor of Medicine

Cleveland Clinic Taussig Cancer Institute Glickman Urological and Kidney Institute

Cleveland, Ohio

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting April 12, 2016

FINAL MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Phuong Khanh (P.K.) Morrow, MD, FACP

Executive Medical Director, Amgen Oncology Therapeutic Area Head, US Medical Organization Thousand Oaks, California

TEMPORARY MEMBERS (Voting)

William Douglas Figg, Sr., PharmD, MBA

Senior Investigator and Head of the Clinical Pharmacology Program in the Office of the Clinical Director, Center for Cancer Research (CCR) National Cancer Institute (NCI) National Institutes of Health (NIH) Head of Molecular Pharmacology Section Deputy Branch Chief in the Genitourinary Malignancies Branch, CCR, NCI, NIH Bethesda, Maryland

Donald E. Mager, PharmD, PhD

Associate Professor of Pharmaceutical Sciences Department of Pharmaceutical Sciences University at Buffalo, State University of New York Buffalo, New York

Arun Rajan, MD

Associate Research Physician Thoracic and GI Oncology Branch CCR, NCI, NIH Bethesda, Maryland

Terry Gillespie

(Patient Representative)
Westmont, Illinois

Michele Orza, ScD

(Acting Consumer Representative)
Senior Advisor to the Executive Director
Patient-Centered Outcomes Research Institute
(PCORI)
Washington, District of Columbia

Eva Szabo, MD

Chief Lung & Upper Aerodigestive Cancer Research Group Division of Cancer Prevention, NCI, NIH Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting April 12, 2016

FINAL MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director Office of Hematology and Oncology Products (OHOP) Office of New Drugs (OND), CDER, FDA

Gideon Blumenthal, MD

Medical Team Leader Thoracic/Head & Neck Cancer Team DOP2, OHOP, OND, CDER, FDA

Chao Liu, PhD

Pharmacometrics Reviewer
Division of Pharmacometrics (DPM)
Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS)
CDER, FDA

Patricia Keegan, MD

Director Division of Oncology Products 2 (DOP2) OHOP, OND, CDER, FDA

'Lola Fashoyin-Aje, MD, MPH

Medical Officer Thoracic/Head & Neck Cancer Team DOP2, OHOP, OND, CDER, FDA